Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Metastasis-Directed Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer Recurrence Revealed by Choline PET/CT

Metastasis-Directed Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer... We report a 49-year-old male with castration-resistant prostate cancer (CRPC) with oligometastasis diagnosed by <sup>11</sup>C-choline positron emission tomography-computed tomography (PET/CT) and treated with target radiotherapy. In the diagnosis of CRPC (serum prostate-specific antigen [PSA] level of 6.53 ng/mL after maximum androgen blockade (MAB) therapy, high-dose brachytherapy, and external beam radiotherapy), <sup>11</sup>C-choline PET/CT detected one tiny obturator lymph node metastasis which fluorodeoxyglucose PET/CT could not detect. He underwent intensity-modulated radiation therapy and MAB was restarted. The PSA value decreased and reached nadir (0.091 ng/mL) after 6 months. The time to PSA progression was 10 months. The choline PET/CT finding and the corresponding local treatment could play an important role in the management sequence of oligoprogressive CRPC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Case Reports in Oncology Karger

Metastasis-Directed Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer Recurrence Revealed by Choline PET/CT

Download PDF
4 pages

Loading next page...
 
/lp/karger/metastasis-directed-radiotherapy-for-oligoprogressive-castration-SbEBz8v6I2

References (8)

Publisher
Karger
Copyright
© 2021 The Author(s). Published by S. Karger AG, Basel
eISSN
1662-6575
DOI
10.1159/000512068
Publisher site
See Article on Publisher Site

Abstract

We report a 49-year-old male with castration-resistant prostate cancer (CRPC) with oligometastasis diagnosed by <sup>11</sup>C-choline positron emission tomography-computed tomography (PET/CT) and treated with target radiotherapy. In the diagnosis of CRPC (serum prostate-specific antigen [PSA] level of 6.53 ng/mL after maximum androgen blockade (MAB) therapy, high-dose brachytherapy, and external beam radiotherapy), <sup>11</sup>C-choline PET/CT detected one tiny obturator lymph node metastasis which fluorodeoxyglucose PET/CT could not detect. He underwent intensity-modulated radiation therapy and MAB was restarted. The PSA value decreased and reached nadir (0.091 ng/mL) after 6 months. The time to PSA progression was 10 months. The choline PET/CT finding and the corresponding local treatment could play an important role in the management sequence of oligoprogressive CRPC.

Journal

Case Reports in Oncology – Karger

Published: Jan 1, 2021

Keywords: Castration-resistant prostate cancer; Oligometastasis; Choline PET/CT

There are no references for this article.